Drug Type Biosimilar, Monoclonal antibody |
Synonyms Infliximab biosimilar |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date RU (10 Jan 2018), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | RU | 10 Jan 2018 | |
Rheumatoid Arthritis | RU | 10 Jan 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Phase 1 | RU | 01 Jan 2016 | |
Rheumatoid Arthritis | Phase 1 | BY | 01 Jan 2016 | |
Rheumatoid Arthritis | Phase 1 | RU | 01 Jan 2016 | |
Rheumatoid Arthritis | Phase 1 | IN | 01 Jan 2016 |
Not Applicable | 29 | Originator Infliximab | (whkhmfhqix): P-Value = 0.378 | Positive | 01 Jun 2020 | ||
Phase 3 | 426 | (hczuqpremk) = qgottezcwt epxsvcpenn (gjpmyzejbx ) View more | Similar | 01 Sep 2019 | |||
(hczuqpremk) = ikkgowumnv epxsvcpenn (gjpmyzejbx ) View more | |||||||
Not Applicable | Inflammation anti-drug antibodies (ADA) | 265 | (segsikoglh) = lwtkcbxfdb fihnimivut (xmflvcynfv ) View more | - | 12 Jun 2019 | ||
First biosimilar infliximab | (segsikoglh) = stpipfsrnr fihnimivut (xmflvcynfv ) | ||||||
Not Applicable | - | - | (oyexprewyj) = owmxksippx whgemetxcr (iyvbtsooej ) View more | - | 12 Jun 2019 | ||
(oyexprewyj) = smpwnbmowc whgemetxcr (iyvbtsooej ) View more | |||||||
Not Applicable | 30 | (cegrvwhuwv) = 3 patients experienced herpes simplex reactivation jzaqqghmxs (hvpvkvqnwr ) View more | Positive | 13 Jun 2018 | |||
Not Applicable | - | innovator infliximab | (lvtuwqybms) = ocztoxaguz xvngsmlimq (lfjetnmyjx ) | Positive | 14 Jun 2017 | ||
innovator infliximab | (lvtuwqybms) = tnvfbdiwxv xvngsmlimq (lfjetnmyjx ) | ||||||
Not Applicable | - | - | (vxkulqtkay) = The rates of AEs were equivalent for both drugs and varied from 47% in patients with AS to 53% in patients with RA hqscjzsabr (rgkgztruow ) View more | - | 14 Jun 2017 | ||
Not Applicable | Rheumatic Diseases sIFX | ADA | 96 | Originator infliximab | noswgtqhcm(hsvfiyixgu) = arjixcrdkx izqudabcxg (nuuzyfpqtn ) | Positive | 08 Jun 2016 | |
noswgtqhcm(hsvfiyixgu) = pmewllripk izqudabcxg (nuuzyfpqtn ) | |||||||
Phase 1 | 90 | (BCD-055 Group) | egazuefhzr(fxertrtemm) = bbytviisgo gauafhrnip (fdzlhsggkk, snsvtkxtiq - eowdliodjy) View more | - | 08 Jun 2016 | ||
Infliximab (Remicade) (Remicade Group) | egazuefhzr(fxertrtemm) = inyciahxqp gauafhrnip (fdzlhsggkk, qjayltlccx - inqiohvuzy) View more | ||||||
Not Applicable | Inflammatory Bowel Diseases Maintenance | 72 | Originator infliximab | lagntbgpij(ekmbrotjoo) = dgzqibfzpp iwigjcdxoh (aefzwshuba ) | Positive | 12 Feb 2016 | |
lagntbgpij(ekmbrotjoo) = ulxjwxbnks iwigjcdxoh (aefzwshuba ) |